The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

William J. Sandborn

Division of Gastroenterology and Hepatology

Mayo Clinic





Name/email consistency: high



  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. 2000 - 2011
  • Mayo Clinic, Rochester, MN 55905, USA. 2001 - 2010
  • Division of Gastroenterology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, USA. 2000 - 2008
  • The Clinical Trials Task Force of the International Organization of Inflammatory Bowel Disease. 2002
  • Mayo Clinic and Mayo Foundation, Rochester, USA. 2000


  1. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Sandborn, W.J., Colombel, J.F., Schreiber, S., Plevy, S.E., Pollack, P.F., Robinson, A.M., Chao, J., Mulani, P. Inflamm. Bowel Dis. (2011) [Pubmed]
  2. State-of-the-art: Immunosuppression and biologic therapy. Sandborn, W.J. Dig. Dis (2010) [Pubmed]
  3. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Sandborn, W.J., Korzenik, J., Lashner, B., Leighton, J.A., Mahadevan, U., Marion, J.F., Safdi, M., Sninsky, C.A., Patel, R.M., Friedenberg, K.A., Dunnmon, P., Ramsey, D., Kane, S. Gastroenterology (2010) [Pubmed]
  4. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Sandborn, W.J., Colombel, J.F., Frankel, M., Hommes, D., Lowder, J.N., Mayer, L., Plevy, S., Stokkers, P., Travis, S., Van Assche, G., Baumgart, D.C., Targan, S.R. Gut (2010) [Pubmed]
  5. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Sandborn, W.J., Regula, J., Feagan, B.G., Belousova, E., Jojic, N., Lukas, M., Yacyshyn, B., Krzeski, P., Yeh, C.H., Messer, C.A., Hanauer, S.B. Gastroenterology (2009) [Pubmed]
  6. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Sandborn, W.J., Rutgeerts, P., Feagan, B.G., Reinisch, W., Olson, A., Johanns, J., Lu, J., Horgan, K., Rachmilewitz, D., Hanauer, S.B., Lichtenstein, G.R., de Villiers, W.J., Present, D., Sands, B.E., Colombel, J.F. Gastroenterology (2009) [Pubmed]
  7. How to avoid treating irritable bowel syndrome with biologic therapy for inflammatory bowel disease. Sandborn, W.J. Dig. Dis (2009) [Pubmed]
  8. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?. Sandborn, W.J. J. Clin. Gastroenterol. (2008) [Pubmed]
  9. Initial combination therapy in early Crohn's disease. Sandborn, W.J. Lancet (2008) [Pubmed]
  10. Certolizumab pegol for the treatment of Crohn's disease. Sandborn, W.J., Feagan, B.G., Stoinov, S., Honiball, P.J., Rutgeerts, P., Mason, D., Bloomfield, R., Schreiber, S. N. Engl. J. Med. (2007) [Pubmed]
  11. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Colombel, J.F., Panaccione, R., D'Haens, G., Li, J., Rosenfeld, M.R., Kent, J.D., Pollack, P.F. Ann. Intern. Med. (2007) [Pubmed]
  12. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Sandborn, W.J., Feagan, B.G., Lichtenstein, G.R. Aliment. Pharmacol. Ther. (2007) [Pubmed]
  13. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Sandborn, W.J., Hanauer, S.B., Rutgeerts, P., Fedorak, R.N., Lukas, M., MacIntosh, D.G., Panaccione, R., Wolf, D., Kent, J.D., Bittle, B., Li, J., Pollack, P.F. Gut (2007) [Pubmed]
  14. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Sandborn, W.J., Kamm, M.A., Lichtenstein, G.R., Lyne, A., Butler, T., Joseph, R.E. Aliment. Pharmacol. Ther. (2007) [Pubmed]
  15. Preliminary data on the use of apheresis in inflammatory bowel disease. Sandborn, W.J. Inflamm. Bowel Dis. (2006) [Pubmed]
  16. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Sandborn, W.J., Stenson, W.F., Brynskov, J., Lorenz, R.G., Steidle, G.M., Robbins, J.L., Kent, J.D., Bloom, B.J. Clin. Gastroenterol. Hepatol. (2006) [Pubmed]
  17. What's new: innovative concepts in inflammatory bowel disease. Sandborn, W.J. Colorectal. Dis (2006) [Pubmed]
  18. Natalizumab induction and maintenance therapy for Crohn's disease. Sandborn, W.J., Colombel, J.F., Enns, R., Feagan, B.G., Hanauer, S.B., Lawrance, I.C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S., van Deventer, S., Goldblum, R., Despain, D., Hogge, G.S., Rutgeerts, P. N. Engl. J. Med. (2005) [Pubmed]
  19. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Sandborn, W.J., Loftus, E.V. Gut (2004) [Pubmed]
  20. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Sandborn, W.J., Hanauer, S.B., Buch, A. Aliment. Pharmacol. Ther. (2004) [Pubmed]
  21. Pharmacogenomics and IBD: TPMT and thiopurines. Sandborn, W.J. Inflamm. Bowel Dis. (2004) [Pubmed]
  22. Biologics in inflammatory bowel disease: how much progress have we made?. Sandborn, W.J., Faubion, W.A. Gut (2004) [Pubmed]
  23. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Sandborn, W.J., Feagan, B.G., Radford-Smith, G., Kovacs, A., Enns, R., Innes, A., Patel, J. Gut (2004) [Pubmed]
  24. Clinical management of pouchitis. Sandborn, W.J., Pardi, D.S. Gastroenterology (2004) [Pubmed]
  25. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Sandborn, W.J., Hanauer, S.B. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  26. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Sandborn, W.J., Sands, B.E., Wolf, D.C., Valentine, J.F., Safdi, M., Katz, S., Isaacs, K.L., Wruble, L.D., Katz, J., Present, D.H., Loftus, E.V., Graeme-Cook, F., Odenheimer, D.J., Hanauer, S.B. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  27. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Sandborn, W.J., Present, D.H., Isaacs, K.L., Wolf, D.C., Greenberg, E., Hanauer, S.B., Feagan, B.G., Mayer, L., Johnson, T., Galanko, J., Martin, C., Sandler, R.S. Gastroenterology (2003) [Pubmed]
  28. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm. Sandborn, W.J., Feagan, B.G. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  29. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Sandborn, W.J. Curr. Gastroenterol. Rep (2003) [Pubmed]
  30. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Sandborn, W.J., Feagan, B.G., Hanauer, S.B., Lochs, H., Löfberg, R., Modigliani, R., Present, D.H., Rutgeerts, P., Schölmerich, J., Stange, E.F., Sutherland, L.R. Gastroenterology (2002) [Pubmed]
  31. Biologic therapy of inflammatory bowel disease. Sandborn, W.J., Targan, S.R. Gastroenterology (2002) [Pubmed]
  32. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Sandborn, W.J., Loftus, E.V., Colombel, J.F., Fleming, K.A., Seibold, F., Homburger, H.A., Sendid, B., Chapman, R.W., Tremaine, W.J., Kaul, D.K., Wallace, J., Harmsen, W.S., Zinsmeister, A.R., Targan, S.R. Inflamm. Bowel Dis. (2001) [Pubmed]
  33. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Sandborn, W.J., Hanauer, S.B., Katz, S., Safdi, M., Wolf, D.G., Baerg, R.D., Tremaine, W.J., Johnson, T., Diehl, N.N., Zinsmeister, A.R. Gastroenterology (2001) [Pubmed]
  34. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Sandborn, W., Sutherland, L., Pearson, D., May, G., Modigliani, R., Prantera, C. Cochrane. Database. Syst. Rev (2000) [Pubmed]
  35. Pharmacotherapy for inducing and maintaining remission in pouchitis. Sandborn, W., McLeod, R., Jewell, D. Cochrane. Database. Syst. Rev (2000) [Pubmed]
  36. Steroid-dependent Crohn's disease. Sandborn, W.J. Can. J. Gastroenterol. (2000) [Pubmed]
  37. Clinical pharmacology of inflammatory bowel disease therapies. Sandborn, W.J., Faubion, W.A. Curr. Gastroenterol. Rep (2000) [Pubmed]
WikiGenes - Universities